Mounjaro is not purely a GLP-1 drug. It activates GLP-1 receptors, but it also activates a second receptor called GIP, making it a dual-action medication. This distinction matters because it works through a broader mechanism than single-target GLP-1 drugs like Ozempic or Wegovy, and that difference shows up in clinical results.
How Mounjaro Differs From Pure GLP-1 Drugs
GLP-1 receptor agonists mimic a natural gut hormone called GLP-1 that your body releases after eating. This hormone signals your pancreas to produce insulin, slows digestion, and reduces appetite. Drugs like semaglutide (sold as Ozempic and Wegovy) work exclusively on this one pathway.
Mounjaro’s active ingredient, tirzepatide, was the first FDA-approved drug to target both GLP-1 and GIP receptors simultaneously. GIP (glucose-dependent insulinotropic polypeptide) is another natural incretin hormone your body produces after meals. It plays its own role in insulin release and fat metabolism. By activating both receptor systems at once, tirzepatide essentially pulls two levers instead of one. This dual mechanism is thought to explain why Mounjaro tends to produce greater reductions in blood sugar and body weight compared to GLP-1-only medications.
So while Mounjaro is often grouped with “GLP-1 drugs” in casual conversation, and it does act on GLP-1 receptors, calling it simply a GLP-1 agonist leaves out half the picture.
What Mounjaro Is Approved For
The FDA approved Mounjaro for type 2 diabetes management alongside diet and exercise. The same active ingredient, tirzepatide, is also sold under the brand name Zepbound, which is specifically approved for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition like high blood pressure or high cholesterol. Same molecule, two brand names, two distinct approved uses.
Blood Sugar and Weight Loss Results
In the SURPASS-1 clinical trial, participants with type 2 diabetes started with an average A1C of 7.9%. After treatment, those on the 5 mg dose saw their A1C drop by 1.87 percentage points. The 10 mg dose reduced it by 1.89 points, and the 15 mg dose brought it down by 2.07 points. Those are substantial reductions. For context, many diabetes medications aim to lower A1C by about 1 percentage point, so tirzepatide roughly doubled that benchmark at its highest dose.
The weight loss results have drawn even more attention. The dual GIP/GLP-1 mechanism appears to produce more weight loss than GLP-1-only drugs, which is a key reason researchers developed this combination approach in the first place.
How the Dosing Works
Mounjaro is a once-weekly injection. You start at 2.5 mg for the first four weeks, which is a lower introductory dose designed to let your body adjust. After that, the dose increases to 5 mg weekly. If more blood sugar control is needed, your dose can go up in 2.5 mg steps, with at least four weeks between each increase. The maximum dose is 15 mg per week. This gradual ramp-up helps minimize side effects, particularly the gut-related ones that tend to hit hardest early on.
Common Side Effects
Because Mounjaro activates GLP-1 receptors, it shares the digestive side effects common to the entire GLP-1 drug class. Nausea affects up to 18% of patients, diarrhea up to 17%, and vomiting up to 9%. These symptoms are most common during dose increases and typically improve as your body adjusts over the following weeks. Eating smaller meals and avoiding fatty or greasy foods can help reduce the severity.
The medication also carries a boxed warning related to thyroid tumors. It is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. This warning applies to all drugs in the GLP-1 class, not just Mounjaro.
Why It Gets Lumped in With GLP-1s
The confusion is understandable. Mounjaro does activate GLP-1 receptors, it produces similar (and often greater) effects to GLP-1 drugs, and it shares the same general side effect profile. Pharmacies, insurance companies, and even some prescribers refer to it as a GLP-1 for simplicity. But the more precise term is “dual GIP/GLP-1 receptor agonist.” If you’re comparing medications or discussing options with a provider, that distinction is worth knowing, because the added GIP activity is a genuine pharmacological difference, not just a marketing claim.